• April 3, 2016

    Press Release Spotlight

    Stealth BioTherapeutics Announces Presentation of Elamipretide Data at ACC

    Read the full article

    Trial results support further study of elamipretide in heart failure BOSTON – April 3, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing investigational drugs for treating mitochondrial dysfunction, announced promising results from the Phase 1 PREVIEW trial evaluating elamipretide (formerly known as Bendavia) in heart failure patients with reduced ejection fraction. The results… Continue Reading >

    Read the full Press Release
  • March 8, 2016

    Press Release Spotlight

    Stealth BioTherapeutics Initiates Phase 2 Clinical Study of Elamipretide in Fuchs’ Corneal Endothelial Dystrophy

    Read the full article

    Top-line data expected Q3 2016 for mitochondria-targeted treatment for debilitating eye condition BOSTON – March 8, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing drug candidates for treating mitochondrial dysfunction, today announced the initiation of ReVEAL, a Phase 2 clinical study evaluating the topical eye drop formulation of elamipretide (formerly known as Ocuvia)… Continue Reading >

    Read the full Press Release
  • March 3, 2016

    Press Release Spotlight

    Stealth BioTherapeutics to Present at Cowen & Co. 36th Annual Health Care Conference

    Read the full article

    BOSTON – March 1, 2016 – Stealth BioTherapeutics, a clinical-stage biopharmaceutical company developing drug candidates for treating mitochondrial dysfunction, today announced that Reenie McCarthy, Chief Executive Officer of Stealth, will present at the Cowen & Co. 36th Annual Health Care Conference at 12:00 p.m. ET on Tuesday, March 8, 2016 in Boston. Stealth BioTherapeutics: Leading… Continue Reading >

    Read the full Press Release
  • January 7, 2016

    Press Release Spotlight

    Stealth BioTherapeutics Receives FDA Fast Track Designation for Rare Disease Indication

    Read the full article

    Potential therapeutic for primary mitochondrial myopathy associated with genetic mitochondrial disease BOSTON – January 7, 2016 – Stealth BioTherapeutics (Stealth), a biopharmaceutical company developing drug candidates for treating mitochondrial dysfunction, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for MTP-131 (also known as Bendavia) for the treatment of… Continue Reading >

    Read the full Press Release
  • September 9, 2015

    Article Spotlight

    The Site of Intracellular Metabolism May Be a Relevant Drug Target in Dry AMD

    Read the full article

    In the May/June cover story of Retina Today, Scott W. Cousins, MD, offers insights into how our investigational mitochondrial targeted drug Ocuvia (MTP-131) may help treat age-related macular degeneration (AMD). AMD accounts for 54% of all blindness in Americans of European ancestry and 5% globally. It is the most common cause of blindness in the… Continue Reading >

    Read the full Article
  • June 25, 2015

    Press Release Spotlight

    Stealth BioTherapeutics Announces Results in Ocuvia Diabetic Macular Edema Study: The ReVIEW Trial

    Read the full article

    Promising data highlighted during Mitochondrial Science and Medicine Series BOSTON – June 25, 2015 – Stealth BioTherapeutics (Stealth), a biopharmaceutical company developing drug candidates for treating mitochondrial dysfunction, today announced results from its ReVIEW study of Ocuvia in diabetic macular edema (DME) patients. The results were presented in New York City at Stealth’s second Mitochondrial Science… Continue Reading >

    Read the full Press Release
  • April 27, 2015

    Press Release Spotlight

    Stealth BioTherapeutics Expands Ocuvia’s Clinical Development into Rare Mitochondrial Optic Neuropathies

    Read the full article

    Ocuvia is one of the first investigational drugs with potential to treat inherited optic neuropathies common in over 20 genetic mitochondrial diseases Boston, MA – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing drug candidates for mitochondrial dysfunction, today announced expansion of its ophthalmology program with FDA granting a Type B meeting for inherited optic… Continue Reading >

    Read the full Press Release

Stealth BioTherapeutics Announces Presentation of Elamipretide Data at ACC

Trial results support further study of elamipretide in heart failure BOSTON – April 3, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing investigational drugs for treating mitochondrial dysfunction, announced promising results from the Phase 1 PREVIEW trial evaluating elamipretide (formerly known as Bendavia) in heart failure patients with reduced ejection fraction. The results… Continue Reading >

Stealth BioTherapeutics Initiates Phase 2 Clinical Study of Elamipretide in Fuchs’ Corneal Endothelial Dystrophy

Top-line data expected Q3 2016 for mitochondria-targeted treatment for debilitating eye condition BOSTON – March 8, 2016 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing drug candidates for treating mitochondrial dysfunction, today announced the initiation of ReVEAL, a Phase 2 clinical study evaluating the topical eye drop formulation of elamipretide (formerly known as Ocuvia)… Continue Reading >

Stealth BioTherapeutics to Present at Cowen & Co. 36th Annual Health Care Conference

BOSTON – March 1, 2016 – Stealth BioTherapeutics, a clinical-stage biopharmaceutical company developing drug candidates for treating mitochondrial dysfunction, today announced that Reenie McCarthy, Chief Executive Officer of Stealth, will present at the Cowen & Co. 36th Annual Health Care Conference at 12:00 p.m. ET on Tuesday, March 8, 2016 in Boston. Stealth BioTherapeutics: Leading… Continue Reading >

Stealth BioTherapeutics Receives FDA Fast Track Designation for Rare Disease Indication

Potential therapeutic for primary mitochondrial myopathy associated with genetic mitochondrial disease BOSTON – January 7, 2016 – Stealth BioTherapeutics (Stealth), a biopharmaceutical company developing drug candidates for treating mitochondrial dysfunction, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for MTP-131 (also known as Bendavia) for the treatment of… Continue Reading >